Breast cancer survival among Japanese individuals and US residents of Japanese and other origins: a comparative registry-based study.

Breast / pathology Breast Neoplasms / epidemiology Female Humans Japan / epidemiology Kaplan-Meier Estimate Neoplasm Staging Proportional Hazards Models Registries SEER Program
Breast neoplasms Ethnic groups Japan Survival analysis United states

Journal

Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104

Informations de publication

Date de publication:
Nov 2020
Historique:
received: 07 03 2020
accepted: 08 08 2020
pubmed: 21 8 2020
medline: 24 6 2021
entrez: 21 8 2020
Statut: ppublish

Résumé

Breast cancer survival outcomes vary across different ethnic groups. We clarified the differences in clinicopathological and survival characteristics of breast cancer among Japanese, US residents with Japanese origin (USJ), and US residents with other origins (USO). Using Surveillance, Epidemiology, and End Results (SEER) 18 dataset and Japanese Breast Cancer Society (JBCS) registry, we included patients first diagnosed with breast cancer between 2004 and 2015. We categorized the patients into three groups based on the database and the recorded ethnicity: Japanese (all those from the JBCS registry), USJ (those from SEER with ethnicity: Japanese), and USO (those from SEER with ethnicity other than Japanese). Excluding patients diagnosed after 2012, stage 0, and 4 patients, we examined the overall survival (OS) and breast cancer-specific survival (BCSS) using the Kaplan-Meier method and Cox proportional hazards models, adjusting for age, sex, cancer stage, and hormone receptor (HR) status. We identified 7362 USJ, 701,751 USO, and 503,013 Japanese breast cancer patients. The proportion of HR-positive breast cancer was the highest among USJ (71%). OS was significantly longer among Japanese and USJ than USO (Hazard ratio 0.46; 95% Confidence Interval [CI] 0.45-0.47 for Japanese and 0.66 [95% CI 0.59-0.74] for USJ) after adjusting for baseline covariates. BCSS was also significantly higher in the two groups (HR 0.53 [95% CI 0.51-0.55] for Japanese and 0.53 [95% CI 0.52-0.74] for USJ). In stage I-III breast cancer, Japanese and US residents with Japanese origin experienced significantly longer survival than US residents with non-Japanese origins.

Sections du résumé

BACKGROUND BACKGROUND
Breast cancer survival outcomes vary across different ethnic groups. We clarified the differences in clinicopathological and survival characteristics of breast cancer among Japanese, US residents with Japanese origin (USJ), and US residents with other origins (USO).
METHOD METHODS
Using Surveillance, Epidemiology, and End Results (SEER) 18 dataset and Japanese Breast Cancer Society (JBCS) registry, we included patients first diagnosed with breast cancer between 2004 and 2015. We categorized the patients into three groups based on the database and the recorded ethnicity: Japanese (all those from the JBCS registry), USJ (those from SEER with ethnicity: Japanese), and USO (those from SEER with ethnicity other than Japanese). Excluding patients diagnosed after 2012, stage 0, and 4 patients, we examined the overall survival (OS) and breast cancer-specific survival (BCSS) using the Kaplan-Meier method and Cox proportional hazards models, adjusting for age, sex, cancer stage, and hormone receptor (HR) status.
RESULTS RESULTS
We identified 7362 USJ, 701,751 USO, and 503,013 Japanese breast cancer patients. The proportion of HR-positive breast cancer was the highest among USJ (71%). OS was significantly longer among Japanese and USJ than USO (Hazard ratio 0.46; 95% Confidence Interval [CI] 0.45-0.47 for Japanese and 0.66 [95% CI 0.59-0.74] for USJ) after adjusting for baseline covariates. BCSS was also significantly higher in the two groups (HR 0.53 [95% CI 0.51-0.55] for Japanese and 0.53 [95% CI 0.52-0.74] for USJ).
CONCLUSIONS CONCLUSIONS
In stage I-III breast cancer, Japanese and US residents with Japanese origin experienced significantly longer survival than US residents with non-Japanese origins.

Identifiants

DOI: 10.1007/s10549-020-05869-y PMID: 32816191
pubmed: 32816191
doi: 10.1007/s10549-020-05869-y
pii: 10.1007/s10549-020-05869-y
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

585-596

Subventions

Organisme : the Japanese Breast Cancer Society (JBCS)
ID : 17003

Références

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424. https://doi.org/10.3322/caac.21492
doi: 10.3322/caac.21492
Waks AG, Winer EP (2019) Breast cancer treatment. JAMA 321(3):288. https://doi.org/10.1001/jama.2018.19323
doi: 10.1001/jama.2018.19323 pubmed: 30667505 pmcid: 30667505
Genentech (1998) Biotechnology Breakthrough In Breast Cancer Wins FDA Approval, Press Releases|Friday, Sep 25, 1998. https://www.gene.com/media/press-releases/4763/1998–09–25/biotechnology-breakthrough-in-breast-can . Accessed September 25, 2019.
Yeo W, Ueno T, Lin C-H et al (2019) Treating HR+/HER− breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression. Breast Cancer Res Treat. https://doi.org/10.1007/s10549-019-05318-5
doi: 10.1007/s10549-019-05318-5 pubmed: 31270763 pmcid: 31270763
Costa RLB, Gradishar WJ (2017) Differences are important: breast cancer therapy in different ethnic groups. J Glob Oncol 3(4):281–284. https://doi.org/10.1200/jgo.2017.009936
doi: 10.1200/jgo.2017.009936 pubmed: 28831435 pmcid: 5560466
Wakai K, Suzuki S, Ohno Y, Kawamura T, Tamakoshi A, Aoki R (1995) Epidemiology of breast cancer in Japan. Int J Epidemiol. 24(2):285–291
doi: 10.1093/ije/24.2.285 pubmed: 7635587 pmcid: 7635587
Howlader N, Noone A, Krapcho M, et al. (2017) SEER Cancer Statistics Review, 1975–2014. April. https://seer.cancer.gov/csr/1975_2014/ , based on November 2016 SEER data submission, posted to the SEER web site, April 2017, Published 2017.
DeSantis CE, Bray F, Ferlay J, Lortet-Tieulent J, Anderson BO, Jemal A (2015) International variation in female breast cancer incidence and mortality rates. Cancer Epidemiol Biomarkers Prev 24(10):1495–1506. https://doi.org/10.1158/1055-9965.epi-15-0535
doi: 10.1158/1055-9965.epi-15-0535 pubmed: 26359465
Zhang J, Dhakal IB, Zhao Z, Li L (2012) Trends in mortality from cancers of the breast, colon, prostate, esophagus, and stomach in East Asia: role of nutrition transition. Eur J Cancer Prev 21(5):480–489. https://doi.org/10.1097/CEJ.0b013e328351c732
doi: 10.1097/CEJ.0b013e328351c732 pubmed: 22357483
Matsuno RK, Anderson WF, Yamamoto S et al (2007) Early- and late-onset breast cancer types among women in the United States and Japan. Cancer Epidemiol Biomarkers Prev 16(7):1437–1442. https://doi.org/10.1158/1055-9965.EPI-07-0108
doi: 10.1158/1055-9965.EPI-07-0108 pubmed: 17627009 pmcid: 17627009
National Cancer Institute Nationa Cancer Institute DCCPS Surveillancel Research Program (2017) Female breast cancer—cancer stat facts. Surveillance, epidemiology, and end results (SEER) program populations (1969–2016). https://seer.cancer.gov/statfacts/html/breast.html . Published 2017. Accessed June 17, 2019.
Iwamoto T, Fukui N, Kinoshita T et al (2015) Comprehensive prognostic report of the Japanese Breast Cancer Society registry in 2006. Breast Cancer. https://doi.org/10.1007/s12282-015-0646-3
doi: 10.1007/s12282-015-0646-3 pubmed: 26631838 pmcid: 26631838
Curtis E, Quale C, Haggstrom D, Smith-Bindman R (2008) Racial and ethnic differences in breast cancer survival: How much is explained by screening, tumor severity, biology, treatment, comorbidities, and demographics? Cancer 112(1):171–180. https://doi.org/10.1002/cncr.23131
doi: 10.1002/cncr.23131 pubmed: 18040998 pmcid: 18040998
Pineda MD, White E, Kristal AR, Taylor V (2001) Asian breast cancer survival in the US: a comparison between Asian immigrants, US-born Asian Americans and Caucasians. Int J Epidemiol 30(5):976–982. https://doi.org/10.1093/ije/30.5.976
doi: 10.1093/ije/30.5.976 pubmed: 11689507 pmcid: 11689507
Lin SS, Clarke CA, Prehn AW, Glaser SL, West DW, O’Malley CD (2002) Survival differences among Asian subpopulations in the United States after prostate, colorectal, breast, and cervical carcinomas. Cancer 94(4):1175–1182. https://doi.org/10.1002/cncr.10319
doi: 10.1002/cncr.10319 pubmed: 11920489 pmcid: 11920489
National Cancer Institute DCCPS Surveilane Research Program The Surveillance Research Program of the Division of Cancer Control and Population Science (2017) SEER*Stat Database: Incidence - SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2017 Sub (2000–2015) <Katrina/Rita Population Adjustment>.
Tokuda Y, Kumamaru H, Jinno H (2019) The japanese breast cancer society breast cancer registry in the national clinical database: current status and future perspectives to improve outcomes for breast cancer patients. Jpn Surg Soc. 120(6):639–645
Greene FL, Page DL, Fleming ID, et al. (2002) AJCC cancer staging manual. 6th ed. (the American Joint Committee on Cancer, ed.). Springer-Verlag, New York
Cianfrocca M, Goldstein LJ (2004) Prognostic and predictive factors in early-stage breast cancer. Oncologist 9(6):606–616. https://doi.org/10.1634/theoncologist.9-6-606
doi: 10.1634/theoncologist.9-6-606
Uchida K, Ohashi H, Kinoshita S et al (2015) Breast cancer screening and the changing population pyramid of Japan. Breast Cancer 22(2):172–176. https://doi.org/10.1007/s12282-013-0470-6
doi: 10.1007/s12282-013-0470-6 pubmed: 23625276
World Bank (2016) World Bank: population ages 65 and above (% of total). https://data.worldbank.org/indicator/SP.POP.65UP.TO.ZS . Published 2016. Accessed July 23, 2019.
Kurebayashi J, Moriya T, Ishida T et al (2007) The prevalence of intrinsic subtypes and prognosis in breast cancer patients of different races. Breast 16(2 SUPPL.):72–77. https://doi.org/10.1016/j.breast.2007.07.017
doi: 10.1016/j.breast.2007.07.017
Kamineni A, Anderson ML, White E et al (2013) Body mass index, tumor characteristics, and prognosis following diagnosis of early stage breast cancer in a mammographically-screened population. Cancer Causes Control 24(2):305–312. https://doi.org/10.1007/s10552-012-0115-7
doi: 10.1007/s10552-012-0115-7 pubmed: 23224272
Kwan ML, John EM, Caan BJ et al (2014) Obesity and mortality after breast cancer by Race/Ethnicity: The california breast cancer survivorship consortium. Am J Epidemiol 179(1):95–111. https://doi.org/10.1093/aje/kwt233
doi: 10.1093/aje/kwt233 pubmed: 24107615
Ziegler RG, Hoover RN, Pike MC et al (1993) Migration patterns and breast cancer risk in Asian–American women. J Natl Cancer Inst 85(22):1819–1827. https://doi.org/10.1093/jnci/85.22.1819
doi: 10.1093/jnci/85.22.1819 pubmed: 8230262
Pike MC, Kolonel LN, Henderson BE et al (2002) Breast cancer in a multiethnic cohort in Hawaii and Los Angeles: risk factor-adjusted incidence in Japanese equals and in Hawaiians exceeds that in whites. Cancer Epidemiol Biomarkers Prev. 11(9):795–800
pubmed: 12223421
Maeda H, Kurokawa T (2015) Recent trends for drug lag in clinical development of oncology drugs in Japan: does the oncology drug lag still exist in Japan? Int J Clin Oncol 20(6):1072–1080. https://doi.org/10.1007/s10147-015-0825-4
doi: 10.1007/s10147-015-0825-4 pubmed: 25837976
DPE Research Department (2019) The U.S. Health care system. https://international.commonwealthfund.org/countries/united_states/ .
Chambers JD, May KE, Neumann PJ (2013) Medicare covers the majority of FDA-approved devices and part B drugs, but restrictions and discrepancies remain. Health Aff 32(6):1109–1115. https://doi.org/10.1377/hlthaff.2012.1073
doi: 10.1377/hlthaff.2012.1073
Shaw DL, Dhruva SS, Ross JS (2018) Coverage of novel therapeutic agents by medicare prescription drug plans following FDA approval. J Manag Care Spec Pharm 24(12):1230–1238. https://doi.org/10.18553/jmcp.2018.24.12.1230
doi: 10.18553/jmcp.2018.24.12.1230 pubmed: 30479199 pmcid: 30479199
Hsu CD, Wang X, Habif DV, Ma CX, Johnson KJ (2017) Breast cancer stage variation and survival in association with insurance status and sociodemographic factors in US women 18 to 64 years old. Cancer 123(16):3125–3131. https://doi.org/10.1002/cncr.30722
doi: 10.1002/cncr.30722 pubmed: 28440864 pmcid: 28440864
Sakamoto H, Rahman M, Nomura S, et al. (2018) Japan health system review. Vol. 8 No. 1. World Health Organization, Regional Office for South-East Asia. https://apps.who.int/iris/ . Accessed June 21, 2019.
Iqbal J, Ginsburg O, Rochon PA, Sun P, Narod SA (2015) Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States. JAMA 313(2):165–173. https://doi.org/10.1001/jama.2014.17322
doi: 10.1001/jama.2014.17322 pubmed: 25585328 pmcid: 25585328
Rae M (2019) Tax Subsidies for Private Health Insurance – II. Non-Group Coverage – 7779–02 | The Henry J. Kaiser Family Foundation. https://www.kff.org/report-section/tax-subsidies-for-private-health-insurance-ii-non-group-coverage/ . Accessed May 17, 2019.
Ebell MH, Thai TN, Royalty KJ (2018) Cancer screening recommendations: an international comparison of high income countries. Public Health Rev. https://doi.org/10.1186/s40985-018-0080-0
doi: 10.1186/s40985-018-0080-0 pubmed: 29507820 pmcid: 29507820
American Cancer Society (2019) Cancer prevention & early detection facts & figures, 2019–2020
Cancer Information Service (2019) Cancer registry and statistics, National Cancer Center, Japan
Wilson RJ, Zhang K (2014) Coding completeness and quality of relative survival-related variables in the national program of cancer registries cancer surveillance system, 1995–2008. J Registry Manag. 41(2):65–71
pubmed: 25153011 pmcid: 25153011
Process—SEER Quality Improvement (2019s) https://seer.cancer.gov/qi/process.html . Accessed August 7, 2019.
Tomotaki A, Miyata H, Hashimoto H, Murakami A, Ono M (2014) Results of data verification of the Japan congenital cardiovascular database, 2008 to 2009. World J Pediatr Congenit Heart Surg 5(1):47–53. https://doi.org/10.1177/2150135113508794
doi: 10.1177/2150135113508794 pubmed: 24403354
Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ CK (eds) (2019) SEER Cancer Statistics Review, 1975–2014, National Cancer Institute. Bethesda, MD,  https://seer.cancer.gov/csr/1975_2014/ , based on November 2016 SEER data submission, posted to the SEER web site, April 2017

Auteurs

Rin Ogiya (R)

Harvard T H Chan School of Public Health, Boston, USA.
ORCID: 0000-0002-0619-2838

Naoki Niikura (N)

Department of Breast and Endocrine Surgery, Tokai University School of Medicine, 143, Shimokasuya, Isehara, Kanagawa, Japan. niikura@is.icc.u-tokai.ac.jp.
ORCID: 0000-0001-6732-8527

Hiraku Kumamaru (H)

Department of Healthcare Quality Assessment, School of Public Health, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Yoshinori Takeuchi (Y)

Department of Biostatistics, School of Public Health, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Takuho Okamura (T)

Department of Breast and Endocrine Surgery, Tokai University School of Medicine, 143, Shimokasuya, Isehara, Kanagawa, Japan.

Takayuki Kinoshita (T)

Division of Breast Surgery, Tokyo Medical Center, Tokyo, Japan.

Kenjiro Aogi (K)

Division of Clinical Research Promotion, NHO Shikoku Cancer Center, Matsuyama, Japan.

Keisei Anan (K)

Department of Surgery, Kitakyushu Municipal Medical Center, Kitakyushu, Japan.

Kotaro Iijima (K)

Department of Breast Oncology, Juntendo University, Tokyo, Japan.

Takanori Ishida (T)

Department of Breast and Endocrine Surgical Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan.

Takayuki Iwamoto (T)

Department of Breast and Endocrine Surgery, Okayama University Hospital, Okayama, Japan.

Masaaki Kawai (M)

Department of Breast Oncology, Miyagi Cancer Center, Natori, Japan.

Yasuyuki Kojima (Y)

Division of Breast and Endocrine Surgery, Department of Surgery, St. Marianna University School of Medicine, Kawasaki, Japan.

Takashi Sakatani (T)

Department of Diagnostic Pathology, Nippon Medical School Hospital, Tokyo, Japan.

Yasuaki Sagara (Y)

Department of Breast Surgical Oncology, Hakuaikai Medical Cooperation, Sagara Hospital, Kagoshima, Japan.

Naoki Hayashi (N)

Department of Breast Surgical Oncology, St. Luke's International Hospital, Tokyo, Japan.

Hideji Masuoka (H)

Kotoni Breast Clinic, Sapporo, Japan.

Masayuki Yoshida (M)

Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan.

Hiroaki Miyata (H)

Department of Healthcare Quality Assessment, School of Public Health, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Hitoshi Tsuda (H)

Department of Basic Pathology, National Defense Medical College, Tokorozawa, Japan.

Shigeru Imoto (S)

Department of Breast Surgery, Kyorin University Hospital, Mitaka, Japan.

Hiromitsu Jinno (H)

Department of Surgery, Teikyo University School of Medicine, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Régions du corps › Région mammaire › Breast cancer survival among Japanese...
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Maladies du sein › Tumeurs du sein › Breast cancer survival among Japanese...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Breast cancer survival among Japanese...
questionsmedicales.fr › Régions géographiques › Iles › Japon › Breast cancer survival among Japanese...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Analyse de survie › Estimation de Kaplan-Meier › Breast cancer survival among Japanese...
questionsmedicales.fr › Diagnostic › Pronostic › Stadification tumorale › Breast cancer survival among Japanese...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Analyse de survie › Modèles des risques proportionnels › Breast cancer survival among Japanese...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Enregistrements › Breast cancer survival among Japanese...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Enregistrements › Programme SEER › Breast cancer survival among Japanese...